Table 2 Characteristics of included studies
Trials | Country | Study design | Number of participants | Intervention | Comparator | Ref |
|---|---|---|---|---|---|---|
Arjanova et al. | Ukraine | Open-label trial | 40 TB/HIV coinfected patients | Immunoxel with ATT | ATT alone | [15] |
Arjonova et al. | Ukraine | Open-label trail | 40 TB/HIV coinfected patients | Immunoxel with ATT | ATT alone | [6] |
Batbold et al. | Ukraine and Mongolia | Double-blinded placebo controlled RCT | 269 participants | Immunoxel with ATT | ATT with placebo | [5] |
Efremenko et al. | Ukraine | Unblinded RCT | 69 patients, 76.8% with TB and 23.2% with TB/HIV co-infection | Various Immunoxel formulations: sugar dragees, sugar-coated pills, gelatin pastilles and dried honey lozenges | Sugar-coated pills without Immunoxel | [7] |
Zaitzeva et al. | Ukraine | Non-randomised controlled trial | 75 newly PTB patients to assess the adjunct effect of Dzherelo on clinical outcomes and biochemical and blood parameters in patients with cavitary and infiltrating PTB | Immunoxel with ATT | ATT only | [8] |
Zaitzeva et al. | Ukraine | Non-randomised controlled trial | 66 patients of which 48 had MDR-TB | Immunoxel with ATT | ATT alone | [16] |